Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 34, Issue 36, 2016, Pages 4323-4328

  Winn, Aaron N ^a   Keating, Nancy L ^b   Dusetzina, Stacie B ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHARLSON COMORBIDITY INDEX; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RURAL AREA; TREATMENT DURATION; URBAN AREA; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CANCER REGISTRY; COHORT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; ECONOMICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; UTILIZATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICARE; MEDICATION ADHERENCE; PATIENT COMPLIANCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 85009812320     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.4184     Document Type: Article

References (33)

1. Lotvin AM, Shrank WH, Singh SC, et al: Specialty medications: Traditional and novel tools can address rising spending on these costly drugs. Health Aff (Millwood) 33:1736-1744, 2014
2. Conti RM, Fein AJ, Bhatta SS: National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011. Health Aff (Millwood) 33:1721-1727, 2014
3. Murphy CC, Bartholomew LK, Carpentier MY, et al: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res Treat 134:459-478, 2012
4. Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462-467, 2002
5. Cramer JA: A systematic review of adherence with medications for diabetes. Diabetes Care 27:1218-1224, 2004
6. Neuner JM, Kamaraju S, Charlson JA, et al: The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J Natl Cancer Inst 107: djv130, 2015
7. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
8. Gotay C, Dunn J: Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res 11:709-715, 2011
9. Ziller V, Kalder M, Albert US, et al: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431-436, 2009
10. Dusetzina SB, Keating NL: Mind the gap: Why closing the doughnut hole is insufficient for increasing Medicare beneficiary access to oral chemotherapy. J Clin Oncol 34:375-380, 2016
11. Faden RR, Chalkidou K, Appleby J, et al: Expensive cancer drugs: A comparison between the United States and the United Kingdom. Milbank Q 87:789-819, 2009
12. Weingart SN, Brown E, Bach PB, et al: NCCN Task Force report: Oral chemotherapy. J Natl Compr Canc Netw 6:S1-S14, 2008(suppl 3)
13. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
14. Baccarani M, Pileri S, Steegmann JL, et al: Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23: vii72-vii77, 2012(suppl 7)
15. Jabbour E, Kantarjian H: Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91:252-265, 2016
16. Jabbour EJ, Kantarjian H, Eliasson L, et al: Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87:687-691, 2012
17. Warren JL, Klabunde CN, Schrag D, et al: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40: IV-3-IV-18, 2002(suppl)
18. National Cancer Institute: SEER-Medicare linked database. http://healthcaredelivery.cancer. gov/seermedicare
19. Kaiser Family Foundation: Fact Sheet: Medicare Advantage. http://files.kff.org/attachment/Fact-Sheet-Medicare-Advantage
20. Klabunde CN, Legler JM, Warren JL, et al: A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17:584-590, 2007
21. Zou G: A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159:702-706, 2004
22. Yelland LN, Salter AB, Ryan P: Performance of the modified Poisson regression approach for estimating relative risks from clustered prospective data. Am J Epidemiol 174:984-992, 2011
23. Knickman JR, Hunt KA, Snell EK, et al: Wealth patterns among elderly Americans: Implications for health care affordability. Health Aff (Millwood) 22:168-174, 2003
24. Banegas MP, Guy GP Jr, De Moor JS, et al: For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff (Millwood) 35:54-61, 2016
25. Streeter SB, Schwartzberg L, Husain N, et al: Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 7:46s-51s, 2011(suppl)
26. Couto JE, Panchal JM, Lal LS, et al: Geographic variation in medication adherence in commercial and Medicare part D populations. J Manag Care Spec Pharm 20:834-842, 2014
27. Yun H, Safford MM, Brown TM, et al: Statin use following hospitalization among Medicare beneficiaries with a secondary discharge diagnosis of acute myocardial infarction. J Am Heart Assoc 4:e001208, 2015
28. Stuart B, Davidoff A, Erten M, et al: How Medicare Part D benefit phases affect adherence with evidence-based medications following acute myocardial infarction. Health Serv Res 48:1960-1977, 2013
29. Faderl S, Talpaz M, Estrov Z, et al: The biology of chronic myeloid leukemia. N Engl J Med 341:164-172, 1999
30. Quintás-Cardama A, Cortes JE: Chronic myeloid leukemia: Diagnosis and treatment. Mayo Clin Proc 81:973-988, 2006
31. Padula WV, Larson RA, Dusetzina SB, et al: Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst 108: djw003, 2016
32. Conti RM, Padula WV, Larson RA: Changing the cost of care for chronic myeloid leukemia: The availability of generic imatinib in the USA and the EU. Ann Hematol 94:S249-S257, 2015(suppl 2)
33. Kelsall C: Generic imatinib cost-effective firstline treatment for CML. http://www.healio.com/hematology-oncology/leukemia/news/in-the-journals/%7B6ed7ed48-4741-4bd6-ace9-50578005de32%7D/generic-imatinib-cost-effective-first-line-treatment-for-cml